A total of 45 patients were given cytosar and daunorubicin therapy at small doses. Of them 23 patients were with acute nonlymphoblastic leukemia, 12--with hemopoietic dysplasia, and 10--with chronic myeloid leukemia. Cytosar was injected subcutaneously every 12 h at a dose of 10 mg/m2 for 10-25 days, daunorubicin was injected intravenously by drop infusion at a dose of 5 mg/m2. Clinicohematological remission was obtained in 13 patients, clinicohematological improvement in 16. Thus, a positive effect was achieved in 29 patients (64%). The authors provided some data on the influence of small doses of cytosar and daunorubicin on cell maturation in vitro.
